Caffeine impact on neonatal morbidities

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 23, Issue SUPPL. 3, 2010, Pages 20-23

  Aranda, Jacob V ^a   Beharry, Kay ^b   Valencia, Gloria B ^a   Natarajan, Girija ^c   Davis, Jonathan ^d  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apnea of prematurity; bronchopulmonary dysplasia; Caffeine; cerebral palsy; patent ductus; retinopathy of prematurity

Indexed keywords

CAFFEINE; CAFFEINE CITRATE; PLACEBO; THEOPHYLLINE; CENTRAL STIMULANT AGENT;

AGITATION; ARTIFICIAL VENTILATION; BRAIN HEMORRHAGE; BRONCHODILATING ACTIVITY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBRAL PALSY; CLINICAL TRIAL; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DIURESIS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; ELECTROLYTE DISTURBANCE; EXTUBATION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; IRRITABILITY; LOADING DRUG DOSE; LUNG DYSPLASIA; LUNG FUNCTION; LUNG MECHANICS; MAINTENANCE DRUG DOSE; METABOLIC ACIDOSIS; NECROTIZING ENTEROCOLITIS; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN APNEA; NEWBORN MORBIDITY; NEWBORN MORTALITY; NONHUMAN; PATENT DUCTUS ARTERIOSUS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; REVIEW; SIDE EFFECT; TACHYCARDIA; TACHYPNEA; ANIMAL; APNEA; EVALUATION; MORBIDITY; NEWBORN; PREMATURITY;

ANIMALS; APNEA; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MORBIDITY; RESPIRATION, ARTIFICIAL;

EID: 77957937005     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2010.517704     Document Type: Review

References (30)

1. Aranda JV, Gorman W, Bergsteinsson H, Gunn T. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. J Pediatr 1977;90:467-472.
2. Jalal M, Abu-Shaweesh JM, Martin RJ. Neonatal apnea: what s new? Pediatric Pulmonology 2008;43:937-944.
3. Di Fiore JM, Bloom JN, Orge F, Schutt A, Schluchter M, Cheruvu VK, Walsh M, Finer N, Martin RJ. A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity. J Pediatr 2010;157:69-73.
4. Janvier A, Khairy M, Kokkotis A, Cormier C, Messmer D, Barrington KJ. Apnea is associated with neurodevelopmental impairment in very low birth weight infants. J Perinatol 2004;24:763-768.
5. Erenberg A, Leff RD, Haack DG, Mosdell KW, Hicks GM, Wynne BA. Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study. Pharmacotherapy 2000;20:644-652.
6. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W. Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354:2112-2121.
7. Murphy JJ, Swanson T, Ansermino M, Milner R. The frequency of apneas in premature infants after inguinal hernia repair: do they need overnight monitoring in the intensive care unit? J Pediatr Surg 2008;43:865.
8. Henderson-Smart DJ, Steer P. Prophylactic caffeine to prevent postoperative apnea following general anesthesia in preterm infants. Cochrane Database Syst Rev 2001;(4): CD000048.
9. Yoder B, Thomson M, Coalson J. Lung function in immature baboons with respiratory distress syndrome receiving early caffeine therapy: a pilot study. Acta Paediatr 2005;94:92-98.
10. Davis PG, Schmidt B, Roberts RS, Doyle LW, Asztalos E, Haslam R, Sinha S, Tin W; Caffeine for Apnea of Prematurity Trial Group. Caffeine for apnea of prematurity trial: benefits may vary in subgroups. J Pediatr 2010;156:382-387.
11. Kassim Z, Greenough A, Rafferty GF. Effect of caffeine on respiratory muscle strength and lung function in prematurely born, ventilated infants. Eur J Pediatr 2009;168:1491-1495.
12. Henderson-Smart DJ, Davis PG. Prophylactic methylxanthines for extubation in preterm infants. Cochrane Database Syst Rev 2003;(1):CD000139.
13. Steer P, Flenady V, Shearman A, Charles B, Gray PH, Henderson-Smart D, Bury G, Fraser S, Hegarty J, Rogers Y, et al. High dose caffeine citrate for extubation of preterm infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2004;89:F499-F503.
14. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006;117:1113-1121.
15. Clyman RI, Chorne N. Patent ductus arteriosus: evidence for and against treatment. J Pediatr 2007;150:216-219.
16. Fanaroff AA, Stoll BJ, Wright LL, CarloWA, Ehrenkranz RA, Stark AR, Bauer CR, Donovan EF, Korones SB, Laptook AR, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007;196: 147.e1-e8.
17. Chiang MF, Arons RR, Flynn JT, Starren JB. Incidence of retinopathy of prematurity from 1996 to 2000: analysis of a comprehensive New York state patient database. Ophthalmology 2004;111:1317-1325.
18. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. N Engl JMed 2007;357:1893-1902.
19. Gunn TR, Metrakos K, Riley P, Willis D, Aranda JV. Sequelae of caffeine treatment in preterm infants with apnea. J Pediatr 1979;94:106-109.
20. Ment LR, Scott DT, Ehrenkranz RA, Duncan CC. Early childhood developmental follow-up of infants with GMH/IVH: effect of methylxanthine therapy. Am J Perinatol 1985;2:223-227.
21. Turmen T, Davis J, Aranda JV. Relationship of dose and plasma concentrations of caffeine and ventilation in neonatal apnea. Semin Perinatol 1981;5:326-331.
22. Scanlon JE, Chin KC, Morgan ME, Durbin GM, Hale KA, Brown SS. Caffeine or theophylline for neonatal apnoea? Arch Dis Child 1992;67(4 Spec No):425-428.
23. Steer PA, Flenady VJ, Shearman A, Lee TC, Tudehope DI, Charles BG. Periextubation caffeine in preterm neonates: a randomized dose response trial. J Paediatr Child Health 2003;39:511-515.
24. Anderson BJ, Gunn TR, Holford NH, Johnson R. Caffeine overdose in a premature infant: clinical course and pharmacokinetics. Anaesth Intensive Care 1999;27:307-311.
25. Ergenekon E, Dalgic N, Aksoy E, Koc E, Atalay Y. Caffeine intoxication in a premature neonate. Paediatr Anaesth 2001;11:737-739.
26. Natarajan G, Botica ML, Thomas R, Aranda JV. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? Pediatrics. 2007;119:936-940.
27. Aranda JV, Cook CE, Gorman W, Collinge JM, Loughnan PM, Outerbridge EW, Aldridge A, Neims AH. Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. J Pediatr 1979;94:663-668.
28. Charles BG, Townsend SR, Steer PA, Flenady VJ, Gray PH, Shearman A. Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. Ther Drug Monit 2008;30:709-716.
29. Aranda JV, Turmen T. Methylxanthines in apnea of prematurity. Clin Perinatol 1979;6:87-108.
30. Natarajan G, Lopes JM, Aranda JV. Pharmacologic treatment of neonatal apnea. In: Yaffe SJ, Aranda JV, editors. Neonatal and pediatric pharmacology, 4th ed. Philadelphia: Lippincott, Williams and Wilkins; 2010.